中国伤残医学Issue(20)：16-17,2.DOI:10.13214/j.cnki.cjotadm.2014.20.011
恩替卡韦联合a-2b干扰素抗乙肝病毒72周的疗效
Effect of entec avir combined with a-2b interferon on treatment of chronic hepatitis B after th72 week
张志敏 1季宝玉 1李琳 1张聪敏 1陈凤娥1
作者信息
- 1. 河北省衡水市第三人民医院，河北衡水 053000
- 折叠
摘要
Abstract
Objective:To explore the effect of entecavir combined with a -2b interferon (a-2b IFN)on the treatment of chronic hepa-titis B(CHB) after 72weeks.Methods:120 patients of CHB were treated by entecavir (which had been used for the first 4 weeks alone) combining with a-2bIFN.The corse of the treatment was 72 weeks.the changs of serum HBV DNA levels ,HBeAg and HBsAg levels At 48th week and th72 week after treatment were monitored respectively of the 120 patients.R esults:after treatment for 48 weeks,the propor-tion of the 120 patients with undetectable serum HBV DNA was 93.3%;HBeAg loss was observed in 93.3%;HBeAg seroconversion rate reached to 56.7%;none lost HBsAg.At 72 weeks later, the proportion of the 120 patients with undetectable serum HBV DNA increased to 97.5%;the rate of HBeAg loss increased to 94.1%;HBeAg seroconversion rate increased to 70.8%;333.% of the 120 patients lost HBsAg.Conlu ison:Addition of IFNa-2b after entecavir monotherapy of 4 weeks could improve the efficacy when the therapy prolonged from 48 weeks to72 weeks in the treatment for the patients of CHB with high serum HBV DNA levels ,which was worth to popularize .关键词
慢性乙型肝炎/恩替卡韦/a-2b干扰素Key words
Hepatitis B/Entecavir/a-2b interferon分类
医药卫生引用本文复制引用
张志敏,季宝玉,李琳,张聪敏,陈凤娥..恩替卡韦联合a-2b干扰素抗乙肝病毒72周的疗效[J].中国伤残医学,2014,(20):16-17,2.
